HOME >> MEDICINE >> NEWS
Initial results help clinicians identify patients with treatment-resistant depression

Initial results of the nation's largest clinical trial for depression have helped clinicians to track "real world" patients who became symptom-free and to identify those who were resistant to the initial treatment. Participants treated in both medical and specialty mental health care settings experienced a remission of symptoms in 12 to 14 weeks during well-monitored treatment with an antidepressant medication. The study, funded by the National Institutes of Health's (NIH) National Institute of Mental Health (NIMH), used flexible adjustment of dosages based on quick and easy-to-use clinician ratings of symptoms and patient self-ratings of side effects.

About a third of participants reached a remission or virtual absence of symptoms during the initial phase of the study, with an additional 10 to 15 percent experiencing some improvement. Subsequent phases of the trials will help determine successful treatments for the nearly two thirds of those patients who were identified as treatment-resistant to a first medication in phase one.

The trial, known as the STAR*D study -- Sequenced Treatment Alternatives to Relieve Depression -- included 2,876 participants and was conducted over six years at a cost of $35 million. (For more information on STAR*D, go to: http://www.clinicaltrials.gov/ct/show/NCT00021528?order=1).

The medication used in this first phase of the study was the serotonin reuptake inhibitor (SSRI) citalopram (Celexa, made by Forest Pharmaceuticals), and response rates were comparable across the 23 psychiatric and 18 primary care treatment sites. John Rush, M.D., and Madhukar Trivedi, M.D., of the University of Texas Southwestern Medical Center (UTSMC), and colleagues report on the results of phase 1 of STAR*D in the January, 2005 American Journal of Psychiatry.

"The real goal of STAR*D is how best to help the 70 percent of patients for whom treatmen
'"/>

Contact: Jules Asher
NIMHpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health
1-Jan-2006


Page: 1 2 3 4

Related medicine news :

1. UCLA Stroke Center receives American Stroke Associations Initial Achievement Award
2. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
3. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma
4. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
5. Targeted, oral agent Enzastaurin shows favorable results
6. Childhood obesity intervention shows promising results
7. Alpharma presents positive pharmacokinetic study results
8. UCSF brain tumor vaccine trial shows promising results
9. The eyes have it -- Autism research yields surprising results
10. ACP: Residency match results for internal medicine underscore need to redesign primary care
11. Positive results more likely from industry-funded breast cancer trials

Post Your Comments:
(Date:7/21/2014)... PowerObjects, a professional services firm ... add-ons for Microsoft Dynamics CRM, has joined the ... group of the most strategic Microsoft Dynamics partners ... rank them in the highest echelon of the ... the Microsoft Dynamics Inner Circle have performed to ...
(Date:7/21/2014)... have a clot in their legs and are ... medication or undergo a minimally-invasive catheter-based clot removal ... difference in death rates between the two treatments, ... catheter procedure, according to a study by Temple ... a review of more than 90,000 cases nationwide., ...
(Date:7/21/2014)... The "viral reservoir" in which HIV can lie dormant ... earlier than previously thought, new animal research indicates. ... eradicate the AIDS-causing virus, said Harvard researchers working with ... presence of the viral reservoir remains the most significant ... HIV, known as HIV-1. "We found that the ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Western ... “Great College to Work For” by the Chronicle ... and also made the Honor Roll for the ... categories: Collaborative Governance, Compensation and Benefits, Confidence in ... Respect & Appreciation. , “Western University of Health ...
(Date:7/21/2014)... A new study suggests that potential help in lowering ... refrigerator. The study found that regular intake of ... supplements, may help ease the condition. Researchers looked ... probiotics and blood pressure. The studies involved a total ... pressure. People who consumed probiotics had an average ...
Breaking Medicine News(10 mins):Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4Health News:Animal Experiments Shed Light on HIV's Ability to Hide 2Health News:Western University of Health Sciences Elevated to “Great College to Work For” Honor Roll 2Health News:Could Probiotics Help Tame High Blood Pressure? 2
(Date:7/21/2014)... , July 21, 2014 Integrity Applications, ... of the GlucoTrack ® model DF-F noninvasive ... has entered, through its wholly-owned subsidiary, Integrity Applications ... the manufacturing arm of Acer Inc.  Pursuant to ... service (on a non-exclusive basis) the GlucoTrack Model ...
(Date:7/21/2014)... Calif. , July 21, 2014   ... a biopharmaceutical company leading the discovery and development ... the U.S. Food & Drug Administration (FDA) has ... stranded, chemically modified oligonucleotide that binds to and ... therapeutic for the treatment of Alport syndrome, a ...
(Date:7/21/2014)... -- An International Trade Commission (ITC) ruling issued Friday held ... Taiwanese device manufacturer APEX continues to infringe ResMed patents ... is the innovation leader and pioneer in designing and ... "Our research and development teams are constantly ... comfort, performance and efficacy," said David Pendarvis , ...
Breaking Medicine Technology:Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 2Integrity Applications, Inc. Enters into Manufacturing Agreement with Wistron Corp. 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2
Cached News: